Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals (Nasdaq: SNDX) granted inducement stock options covering up to 213,500 common shares to five new employees under its 2023 Inducement Plan.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Syndax Pharmaceuticals (Nasdaq: SNDX) granted inducement stock options covering up to 213,500 common shares to five new employees under its 2023 Inducement Plan.
The options vest over four years: 25% of the underlying shares vest on the first anniversary of the vesting commencement date, followed by 1/48th of the underlying shares monthly over the next 36 months. Vesting is subject to each employee's continued service relationship with Syndax through the applicable vesting dates.
Positive
- None.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.Options covering up to 213,500 common shares create potential dilution upon exercise.
Details
Market move: SNDX -10.33% in the Nov 5 session. inducement stock-option grants
On Nov 5, the first trading day after this news, SNDX closed 10.33% below the previous close. Argus tracked a trough of -7.4% from its starting point during tracking. Our momentum scanner recorded 79 alerts for this stock that day. That session’s volume was 1.6x the stock’s average daily volume.
Data tracked by StockTitan Argus for the Nov 5 session.
Key Figures
- Options subject to grant
- up to 213,500 shares
- Inducement awards for five new employees
- Recipients
- 5 employees
- New employees receiving inducement awards
- Vesting period
- 4 years
- Stock options, subject to continued service
- Initial vesting
- 25%
- On the one-year anniversary of the vesting commencement date
- Subsequent vesting
- 1/48th monthly over 36 months
- After the one-year anniversary
Key Terms
inducement awards financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on November 4, 2026, the Company granted inducement awards to purchase up to 213,500 shares of common stock to five new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.